Longeveron Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
58.8%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$1.5Mnext fiscal year
FY EPS (est.)
-$0.65next fiscal year
Monitoring Framework
Key Performance Indicators
Clinical Trial Revenue Quarterly400KTarget: Growth driven by Bahamas Registry Trial participant demand
Quarterly Net Loss Quarterly-4.7MTarget: Reduction of net loss through disciplined cost management
Cash and Cash Equivalents Quarterly15.8MTarget: Sufficient to fund operations into the fourth quarter of 2026
Watch Items
- ELPIS II Phase 2b Clinical Trial Top-line ResultsTrigger: August 2026 announcementAction: Evaluate clinical efficacy data endpoints and prepare for potential BLA submission in 2027
- Strategic Licensing Partnerships for LaromestrocelTrigger: Execution of licensing agreements across four development programsAction: Assess non-dilutive funding impact and transition to asset-light operating model
- Alzheimer's Disease Phase 2/3 Pivotal Trial InitiationTrigger: Second half of 2026 (contingent on funding/partnering)Action: Monitor securing of non-dilutive funding or strategic partnering support
Research as of 20 Jun 2026